Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

387
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
387
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

384
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
384
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

365
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
365
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

549
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
549
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

403
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
403
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

392
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
392

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Challenges of Performing Controlled Trials of Diet Therapies in Gastroenterology.

JGH open : an open access journal of gastroenterology and hepatology·2026
Same author

Efficacy of gut-brain neuromodulators and brain-gut behaviour therapies for irritable bowel syndrome: systematic review and network meta-analysis.

Gut·2026
Same author

The needs, preferences, and priorities for supportive healthcare in people living with endometriosis: A qualitative exploratory study.

Journal of health psychology·2026
Same author

"She just wants to be a normal kid": Adolescents with inflammatory bowel disease and their caregivers' transition from paediatric to adult care.

British journal of health psychology·2026
Same author

Letter: The Persistence of Anxiety and Depression in Inflammatory Bowel Disease-A Core Phenotype Beyond Inflammatory Activity. Authors' Reply.

Alimentary pharmacology & therapeutics·2026
Same author

Natural History of Psychological Symptoms in Individuals With Rome IV Irritable Bowel Syndrome and Association With Gastrointestinal Symptom Severity.

Neurogastroenterology and motility·2026

Related Experiment Video

Updated: Dec 28, 2025

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.7K

Antidepressants in inflammatory bowel disease.

Antonina Mikocka-Walus1, Alexander C Ford2,3, Douglas A Drossman4,5

  • 1School of Psychology, Deakin University Geelong, Melbourne, VIC, Australia. mikocka@deakin.edu.au.

Nature Reviews. Gastroenterology & Hepatology
|February 20, 2020
PubMed
Summary

Antidepressants can improve gut-brain disorders (DGBI) by treating anxiety, depression, pain, and sleep issues. This perspective explores applying DGBI learnings to optimize inflammatory bowel disease (IBD) management.

More Related Videos

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

458
DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat
09:04

DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat

Published on: February 27, 2014

48.4K

Related Experiment Videos

Last Updated: Dec 28, 2025

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.7K
Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

458
DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat
09:04

DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat

Published on: February 27, 2014

48.4K

Area of Science:

  • Gastroenterology
  • Psychiatry
  • Neuroscience

Background:

  • Gut-brain dysregulation is key to chronic gastrointestinal conditions, leading to the field of psychogastroenterology.
  • Antidepressants, a type of central neuromodulator, are used with psychotherapy for gut-brain disorders, improving psychological and gastrointestinal health.
  • Antidepressants are effective for anxiety, depression, pain, and sleep disturbances often seen in DGBI.

Purpose of the Study:

  • To discuss the application of antidepressants in disorders of gut-brain interaction (DGBI).
  • To explore how insights from DGBI can optimize the management of inflammatory bowel disease (IBD).

Main Methods:

  • This perspective reviews existing literature on antidepressant use in DGBI.
  • It synthesizes findings on the efficacy of antidepressants in comorbid conditions.
  • It proposes applying DGBI knowledge to IBD treatment strategies.

Main Results:

  • Antidepressant efficacy is well-established in DGBI for psychological and physical symptoms.
  • Emerging evidence suggests potential benefits for antidepressants in IBD.
  • Learnings from DGBI can inform IBD management, particularly for associated psychological distress and pain.

Conclusions:

  • Antidepressants represent a valuable therapeutic option for DGBI, addressing multiple symptom domains.
  • Further research is needed to fully elucidate the role and optimize the use of antidepressants in IBD.
  • Integrating psychogastroenterological approaches, including antidepressants, may enhance holistic patient care in IBD.